Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
PRTA Stock Chart & Stats
$9.99
<$0.01(0.07%)
At close: 4:00 PM EST
$9.99
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$4.32 - $17.66
Previous CloseN/A
Volume58.73K
Average Volume (3M)732.47K
Market Cap
$537.76M
Enterprise Value-$34.92M
Total Cash (Recent Filing)$330.84M
Total Debt (Recent Filing)$9.08M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Feb 12, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding53,829,983
10 Day Avg. Volume686,318
30 Day Avg. Volume732,465
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.53
Price to Sales (P/S)5.51
P/FCF Ratio-4.95
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-2.96
Enterprise Value/Gross Profit2.04
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$21.20Price Target Upside112.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe latest Phase 2 data show that coramitug achieved a meaningful NT-proBNP reduction within 12 months, accompanied by favorable echocardiographic changes.
Partnerships And RoyaltiesNovo Nordisk and Roche are funding development while Prothena retains milestones and royalties, creating asymmetric upside not reflected in the current share price.
Undervalued StockProthena's current valuation is seen as overlooking two partnered Phase 3 programs and a Phase 2 asset with blockbuster potential.
Bears Say
Prothena News
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $4.32 and its highest was $17.66 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $537.76M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Feb 12, 2026 which is in 83 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Nov 06, 2025. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.687 by $0.007.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.57.
How many shares outstanding does Prothena have?
Prothena has 53,829,983 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.687. Following the earnings report the stock price went up 4.762%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.20 (112.21% Upside)
$21.20 (112.21% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.39%
12-Months-Change
Fundamentals
Return on Equity
-67.63%
Trailing 12-Months
Asset Growth
-38.18%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc is a clinical-stage biotechnology company focused on the discovery and development of therapies for diseases involving protein misfolding and aggregation, with a primary emphasis on neurodegenerative diseases. The company's core products include monoclonal antibodies and other therapeutic candidates designed to target and modify the underlying biology of these conditions. Prothena operates in the biotechnology sector and is dedicated to advancing innovative approaches to treat diseases such as Alzheimer's and Parkinson's.
PRTA Stock 12 Month Forecast
Average Price Target
$21.20
▲(112.21% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Xoma
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Ownership Overview
24.47% Insiders
19.27% Mutual Funds
19.20% Other Institutional Investors
30.91% Public Companies and
Individual Investors